Published in Hippokratia on June 08, 2015
Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet (2005) 2.97
Evaluation of genetic factors for warfarin dose prediction. Clin Med Res (2007) 2.37
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med (2005) 2.06
Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther (2008) 1.90
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol (2007) 1.50
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res (2006) 1.43
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet (2006) 1.38
Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program (2006) 1.32
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis (2011) 1.30
Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci (2009) 1.21
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics (2011) 1.20
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis. Thromb Res (2009) 1.15
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica (2004) 1.12
Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. Clin Med Res (2005) 0.99
VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur J Clin Pharmacol (2010) 0.98
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost (2010) 0.96
Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med (2009) 0.95
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet (2011) 0.90
Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood (1999) 0.89
Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes. Korean J Physiol Pharmacol (2013) 0.85
A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb (1991) 0.84
Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin Appl Thromb Hemost (2006) 0.83
Warfarin resistance. Cardiovasc J Afr (2008) 0.82
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. Blood Rev (2008) 0.81
VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol (2008) 0.80
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels (2010) 0.80
Warfarin genotyping using three different platforms. Am J Transl Res (2010) 0.80
Association between the -402GA, -401GT, and -323ins10-bp polymorphisms of factor VII gene and breast cancer. Breast Cancer (2010) 0.78
Polymorphisms in the coagulation factor VII gene and risk of primary intracerebral hemorrhage. Eur J Neurol (2007) 0.78
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol (2009) 0.78
Association between polymorphisms in the coagulation factor VII gene and coronary heart disease risk in different ethnicities: a meta-analysis. BMC Med Genet (2011) 0.76
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. Eur J Clin Pharmacol (2011) 0.76
The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement. Medicina (Kaunas) (2011) 0.76